All-Cause and Disease-Specific Mortality in Young Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Nationwide Cohort Study DOI
Jeayeon Park, Goh Eun Chung, Su Jong Yu

и другие.

Опубликована: Янв. 1, 2024

Язык: Английский

Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy DOI Creative Commons
Jihao Xu, Yifan Li,

Zhaolan Feng

и другие.

Cells, Год журнала: 2025, Номер 14(3), С. 221 - 221

Опубликована: Фев. 4, 2025

Cigarette smoke (CS), an intricate blend comprising over 4000 compounds, induces abnormal cellular reactions that harm multiple tissues. Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic (CLD), encompassing non-alcoholic (NAFL), steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). Recently, the term NAFLD has been changed to metabolic dysfunction-associated steatotic (MASLD), NASH renamed (MASH). A multitude of experiments have confirmed association between CS incidence progression MASLD. However, specific signaling pathways involved need be updated with new scientific discoveries. exposure can disrupt lipid metabolism, induce inflammation apoptosis, stimulate fibrosis through promote Currently, there no officially approved efficacious pharmaceutical intervention in clinical practice. Therefore, lifestyle modifications emerged as primary therapeutic approach for managing Smoking cessation application series natural ingredients shown ameliorate pathological changes induced by CS, potentially serving effective decelerating MASLD development. This article aims elucidate which smoking promotes MASLD, while summarizing reversal factors identified recent studies, thereby offering novel insights future research on treatment

Язык: Английский

Процитировано

2
Reply to “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma” DOI Creative Commons
Seogsong Jeong, Won Kim, Sang Min Park

и другие.

Clinical and Molecular Hepatology, Год журнала: 2025, Номер 31(2), С. e208 - e209

Опубликована: Янв. 7, 2025

Язык: Английский

Процитировано

0
Reply to “MAFLD or MASLD: Which Better Represents the Prognosis of the Steatotic Liver Population” DOI Creative Commons
Seogsong Jeong, Won Kim, Sang Min Park

и другие.

Clinical and Molecular Hepatology, Год журнала: 2025, Номер 31(2), С. e210 - e211

Опубликована: Янв. 7, 2025

Язык: Английский

Процитировано

0
A Novel Point-of-Care Prediction Model for Steatotic Liver Disease: Expected Role of Mass Screening in the Global Obesity Crisis DOI Creative Commons
Jeayeon Park, Goh Eun Chung, Yoosoo Chang

и другие.

Gut and Liver, Год журнала: 2025, Номер unknown

Опубликована: Янв. 8, 2025

Jeayeon Park, Goh Eun Chung, Yoosoo Chang, So Kim, Won Sohn, Seungho Ryu, Yunmi Ko, Youngsu Moon Haeng Hur, Yun Bin Lee, Ju Cho, Jeong-Hoon Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl240367

Процитировано

0
Revealing the Importance of a Multidisciplinary Approach to Reducing the Global Burden of SLD Through the COVID-19 Pandemic: Editorial on “Current Burden of Steatotic Liver Disease and Fibrosis among Adults in the United States, 2017-2023” DOI Creative Commons
Jeayeon Park, Su Jong Yu

Clinical and Molecular Hepatology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 16, 2025

Revealing the Importance of a Multidisciplinary Approach to Reducing Global Burden SLD Through COVID-19 Pandemic: Editorial on "Current Steatotic Liver Disease and Fibrosis among Adults in United States, 2017-2023"

Язык: Английский

Процитировано

0
Significant Hepatic Fat Loss after Metabolic Dysfunction-associated Steatotic Liver Disease: Beware of Misclassification as Absence of Disease DOI
Seogsong Jeong

Journal of Hepatology, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
MAFLD or MASLD: Which Better Represents the Prognosis of the Steatotic Liver Population DOI Creative Commons
Ying Wang, Shengfeng Wang, Xiude Fan

и другие.

Clinical and Molecular Hepatology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 26, 2024

Язык: Английский

Процитировано

2
Comment on: Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma DOI Creative Commons
Hai Xu, Zhou Yong,

Huikun Wu

и другие.

Clinical and Molecular Hepatology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 17, 2024

Язык: Английский

Процитировано

1
Dietary Quality, Perceived Health, and Psychological Status as Key Risk Factors for Newly-Developed Metabolic Dysfunction-Associated Steatotic Liver Disease in a Longitudinal Study DOI
Xuangao Wu, Ting Zhang, Sunmin Park

и другие.

Nutrition, Год журнала: 2024, Номер 130, С. 112604 - 112604

Опубликована: Окт. 18, 2024

Язык: Английский

Процитировано

0
All-Cause and Disease-Specific Mortality in Young Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Nationwide Cohort Study DOI
Jeayeon Park, Goh Eun Chung, Su Jong Yu

и другие.

Опубликована: Янв. 1, 2024

Язык: Английский

Процитировано

0